FLUOROQUINOLONES: from structure to activity and toxicity

F. Van Bambeke, Pharm. D. & P. M. Tulkens, MD, PhD

Unité de Pharmacologie Cellulaire et Moléculaire

***Université Catholique de Louvain,* Brussels, Belgium**

www.md.ucl.ac.be/facm

SBIMC / BVIKM

www.sbimc.org - www.bvikm.org

soon...

www.isap.org

Mechanism of action of fluoroquinolones: the basics...



2 key enzymes in DNA replication:

DNA gyrase



topoisomerase IV

bacterial DNA is supercoiled

Ternary complex
DNA - enzyme - fluoroquinolone

COVALENTLY CLOSED
CIRCULAR DNA

DNA GYRASE
catalytic subunits



DNA GYRASE
ATP binding subunits

FLUOROQUINOLONES:

4 stacked molecules

(Shen, *in* Quinolone Antimicrobial Agents, 1993)

Resistance to fluoroquinolones: the basics



Fluoroquinolones are the first entirely man-made antibiotics: do we understand our molecule ?



Don’t panic, we will travel together….

Chemistry and Activity

This is where all begins...

The pharmacophore common to all fluoroquinolones



From chloroquine to nalidixic acid...

chloroquine

1939

1958

7-chloroquinoline
(synthesis intermediate found to display antibacterial activity)

nalidixic acid



1962

Nalidixic acid *



- typical chemical features of fluoroquinolones (a, b, c)
  BUT a naphthridone
  (N at position 8: ⬆)

- limited usefulness as drug
  - narrow antibacterial spectrum (*Enterobacteriaceae* only)
  - short half-life (1.5h)
  - high protein binding (90%)

* Belg. pat. 612,258 to Sterling Drugs, 1962

From nalidixic acid to the 1st fluoroquinolone (1 of 4)

nalidixic acid



1. modify naphthyridone into quinolone

oxolinic acid *



shows reduced protein binding...

* Ger. pat. to Warner Lambert, 1967

* quinoleine

From nalidixic acid to the 1st fluoroquinolone (1 of 4)

nalidixic acid

2. discovery of flumequine *

flumequine *



shows weak but broad Gram(-) activity

* Ger pat. to Rikker Labs, 1973

* benzo-quinolizine

From nalidixic acid to the 1st fluoroquinolone (1 of 4)

nalidixic acid

3. introduce a piperazine *

pipemidic acid *

shows longer half-life...

* Ger. Pat. to Roger Bellon, 1974

* pyrido-2-3-pyrimidine

From nalidixic acid to the 1st fluoroquinolone (1 of 4)

nalidixic acid



combine all 3 features *...

1978

norfloxacin *



broader Gram(-) activity
less protein binding (50%)
longer half-life (3-4h)

* Belgian patent 863,429, 1978 to Kyorin

* 6-fluoro-7-pyrimidino-quinoleine

From norfloxacin to the other 1st generation fluoroquinolones: pefloxacin

norfloxacin



Add a methyl to still increase half-life



pefloxacin *

* Ger. pat. 2,840,910 to Roger Bellon/Dainippon,1979

From norfloxacin to the other 1st generation fluoroquinolones: ofloxacin

norfloxacin



tricyclic compound
(as in flumequine but morpholine ring)

pefloxacin



ofloxacin*

* Eur. pat. Appl. 47,005 to Daiichi, 1982

From norfloxacin to the other 1st generation fluoroquinolones: ciprofloxacin

norfloxacin



cyclopropyl to increase potency

ciprofloxacin *





pefloxacin



ofloxacin

* Ger. pat. 3,142,854 to Bayer AG, 1983

"1st generation" fluoroquinolones

norfloxacin



piperazine

ciprofloxacin



cyclo propyl



methyl

pefloxacin



ofloxacin

morpholine

The "first generation" of fluoroquinolones



- Nalidixic acid
- Oxolinic acid
- Cinoxacin
- Pipemidic acid

- Norfloxacin
- Pefloxacin
- Ofloxacin
- Ciprofloxacin
- Fleroxacin
- Rufloxacin

improved anti Gram (-) activity

	$t_{1/2}$	activity
Norfloxacin	3-4 h	++
Pefloxacin	11 h	+
Ofloxacin	6 h	++
Ciprofloxacin	3-4 h	+++
Fleroxacin		
Rufloxacin		

From ofloxacin to levofloxacin...

Ofloxacin is a racemic mixture





Levofloxacin is the pure (-) S isomer *

The active form of ofloxacin is the (-) S isomer

* Eur. pat. 206,283 to Daiichi, 1987

The present "first generation" of fluoroquinolones ...

- Nalidixic acid
- Oxolinic acid
- Flumequine
- Pipemidic acid

		$t_{1/2}$	activity
• Norfloxacin	improved anti Gram (-) activity	3-4 h	++
• Pefloxacin		11 h	+
• Ofloxacin		6 h	++
• Ciprofloxacin		3-4 h	+++
• Fleroxacin			
• Rufloxacin			
• Levofloxacin		6 h	++++

twice as active as ofloxacin **per g**

How to improve the chemotherapeutic usefulness of the "first generation" fluoroquinolones

1. Maintain broad Gram(-) activity
2. Improve Gram(+) activity
3. Acquire activity against anaerobes





The “second generation” fluoroquinolones



- Temafloxacin [a]
- Sparfloxacin [b]
- Grepafloxacin [c]
- Gatifloxacin [d]

- Gram (-);
- improved Gram (+)

→ anti-anaerobe

a: Toyama, 1988 (?) ; b: Dainippon, 1985-1987; c: Otskuda, 1989; d: Kyorin, 1988

The “third generation” fluoroquinolones

1960 — 1970 — 1980 — 1990 — 2000



- Clinafloxacin [a]
- Trovafloxacin [b]
- Moxifloxacin [c]
- Gemifloxacin [d]

anti-Gram (-)
anti-Gram (+)
anti-anaerobe

a:Kyorin, 1987; b: Pfizer, 1993; c: Bayer, 1994; d: LG Chemical Ltd., S. Korea, 1994-98

1. maintenance of anti - Gram (-) activity



Gram (-) activity (*E. coli*)

I



ciprofloxacin
0.125 - 0.5

II



grepafloxacin
0.06 - 2



gatifloxacin
0.06

2. improving Gram (+) activity (*S. pneumoniae*)



Activity against *S. pneumoniae*

I



ciprofloxacin
0.5 - 2

II



sparfloxacin
0.125 - 0.5



temafloxacin
0.5 - 1

III



moxifloxacin
0.01 - 0.5



trovafloxacin
0.007 - 0.25

3. obtaining activity against anaerobes ...



Activity against *B. fragilis*

I



ciprofloxacin

2 - 128

II

gatifloxacin

0.25 - 8

III



moxifloxacin

0.25 - 8



gemifloxacin

0.5 - 64



trovafloxacin

0.125 - 8

Is there a SAR for emergence of resistance ?

The *"Mutant Prevention Concentration" **

"When Mycobacterium bovis BCG and Staphylococcus aureus were plated on agar containing increasing concentrations of fluoroquinolone, colony numbers exhibited a sharp drop, followed by a plateau and a second sharp drop.

The plateau region correlated,vith the presence of first-step resistant mutants. Mutants were not recovered at concentrations above those required for the second sharp drop, thereby defining a **mutant prevention concentration (MPC)**.

A **C8-methoxy group** lowered the MPC for an N-1-cyclopropyl fluoroquinolone"

Is there a SAR for emergence of resistance ?

Bactericidal activity of FQs against *Mycobaterium bovis*





	PD160793	PD161148
	R = OCH_3	R = H
MIC 99	0.25	0.8
MPC 10	0.9	9
MPC/MIC	3.6	12

Dong *et al*; AAC 43:1756-1758

Fluoroquinolones with a C8-methoxy

I



ciprofloxacin

II

gatifloxacin

III



moxifloxacin

Toxicity

This is where all may fail...

Frequent side effects of fluoroquinolones: is there a SAR ?

COMPLEXATION WITH METALLIC IONS (Fe, Al, Mg, Ca)

PHOTOTOXICITY

DRUG INTERACTIONS: INHIBITION OF cyt P450 (1A2)

CNS TOXICITY (BINDING TO GABA RECEPTOR)

GASTRO-INTESTINAL DISCOMFORT

CARTILAGE and MUSCULOSQUELETAL TOXICITY

SAR of frequent side effects



Binding to GABA receptor

Penetration in CNS

Ca^{++}, Al^{+++}, Fe^{++} complexation

All FQs



Inhibition of P450



cipro, grepa ...

Inhibition of P450

sparflo, flero, lomeflo



Phototoxicity

Fluoroquinolones with low or no drug interactions..

Trova



Gati



Grepa



Moxi



Fluoroquinolones with high phototoxicity ...



Fleroxacin [a]



Lomefloxacin [b]



Bay 3118 [c]



Sparfloxacin

a: Kyorin, 1981; b: Hokuriku, 1985; c: Bayer, 1994

Rare side effects of fluoroquinolones:

RENAL TOXICITY
crystalluria, hematuria, interstitial nephritis, acute renal failure

CARDIAC TOXICITY (QT prolongation, *Torsades de pointe*)

HEPATOTOXICITY
temafloxacin syndrome / trovafloxacin syndrome

Rare side effects of fluoroquinolones: cardiac toxicity

***Torsade de pointes*:** paroxysm of ventricular tachycardia in which the electrocardiogram shows a steady undulation in the QRS axis in runs of 5 to 20 beats with progressive changes in direction. It is a most severe type of arythmia which may cause death. It is most often associated with and preceeded by a prolongation of the QT interval.



Cardiac toxicity QT prolongation: is there any SAR ?



cisapride



astemizole



terfenadine

Cardiac toxicity QT prolongation: is there any SAR ?



cisapride

???



sparfloxacin



grepafloxacin

Other severe toxicities

1992:

The temafloxacin syndrome:

hemolytic uraemic anemia

- discoloured urine, fever
- jaundice, nausea, vomiting
- abdominal pain
- coagulopathy
- hepatic and renal dysfunction

- 0.056% incidence
- 2 deaths

withdrawn in June 1992

1999:

The trovafloxacin syndrome:

serious hepatic events

- laboratory abnormallities
  - ALT, bilirubin, encephalopathies
  - necrotic inflammation

- 0.0056% incidence
- 5 transplants
- 6 deaths (multifactorial)

withdrawn / limited in June 1999

Which part of the molecule is the culprit ?



withdrawn in June 1992

withdrawn / limited in June 1999

Pharmacokinetics



This is where people start sleeping..

SAR of pharmacokinetic parameters



Bulky substituant

$t_{1/2}$ ↗

cipro
grepa
gati
gemi
moxi

flero, peflo, oflo,
grepa, gati,
trova, moxi, gemi

Biodisponibility ↗

V_d ↗

gemi, trova

SAR of main pharmacokinetic parameters:
how to get a long half life









	$t_{1/2}$ (h)	no. of daily administrations
oflo	5 - 7	2 x*
peflo	10	2 x*
flero	9 - 13	1 x
grepa	10 - 12	1 x
gati	13	1 x
gemi	8	1 x
trova	10	1 x
moxi	12	1 x
other FQ	3 - 6	2 x

* higher MIC...

SAR of main pharmacokinetic parameters: biodisponibility



	biodisponibility
trovafloxacin	**90 %**
no data available for gemifloxacin	
other FQ	**60-90 %**

SAR of main pharmacokinetic parameters: volume of distribution



	V_d (L/Kg)
ciprofloxacin	3
gatifloxacin	1.8
grepafloxacin	8
gemifloxacin	1.5
moxifloxacin	2
other FQ	1- 1.5

?

Resistance: do not forget the correct dosing...

“Inadequate dosing of antibiotics is probably an important reason for misuse and subsequent risk of resistance. A recommendation on proper dosing regimens for different infections would be an important part of a comprehensive strategy. The possibility to produce such a dose recommendation based on pharmacokinetic and pharmacodynamic considerations will be further investigated in one of the CPMP working parties…”

European Agency of the Evaluation of Medicinal Products (London)

EMEA discussion paper
on Antimicrobial resistance
3 January 1999 EMEA/9880/99

Pharmacokinetic parameters in relation with efficacy

	Dose (mg)	Cmax (mg/l)	MIC for pk/MIC=10	AUC (mg.h/l)	MIC for AUIC=125
norflo	400 (X2)	1.6	0.2	14	0.1
peflo	400 (X2)	4.6	0.4	108	1.0
cipro	500 (X2)	1.5	0.2	17	0.1
oflo	200 (X2)	3.1	0.4	66	0.4
levoflo	500	8.7	0.8	73	0.4
grepa	600	1.4	0.1	20	0.2
gati	400	4.5	0.4	28	0.2
trova	200	2.3	0.2	25	0.2
moxi	400	2.5	0.2	30	0.2
gemi	*600*	*4*	*0.4*	*24*	*0.2*

Indications of new fluoroquinolones

Consider local epidemiology, and do not believe it is always a first choice…

The use of the FQ should focus on infections in which

- **there is a differential benefit over conventional agents in terms of efficacy, safety, or cost;**
- **in infections for which few alternative treatments exist, or**
- **against organisms towards wich they are sufficiently active to prevent the rapid emergence of resistance.**

Shall we have a very bright future ?